Use of two recipient lists for adults requiring heart transplantation  by Laks, Hillel et al.
Use of two recipient lists for adults requiring heart
transplantation
Hillel Laks, MD
Daniel Marelli, MD
Gregg C. Fonarow, MD
Michele A. Hamilton, MD
Abbas Ardehali, MD
Jaime D. Moriguchi, MD
Jessica Bresson, BS
David Gjertson PhD
Jon A. Kobashigawa, MD
For the UCLA Heart Transplant Group*
See related editorial on page 23
Objective: An alternate (second) adult recipient list was used to match excluded
potential recipients with nonstandard donor hearts that would otherwise be unused.
Methods: The only absolute criterion for entering the alternate recipient list was age:
65 years old before 1998 and 70 years old after that. Group I consisted of alternates
who underwent transplantation, and group II consisted of 401 contemporaneous
recipients. Hearts were first offered to regularly listed patients. At least one of the
following donor risks accounted for allocation to an alternate: coronary artery
disease, reused transplanted heart, high-risk behavior, hepatitis seropositivity, de-
creased left ventricular ejection fraction, high inotropic requirement, left ventricular
hypertrophy, age older than 55 years plus another risk, and small donor with no
other matches.
Results: Of 102 alternates, 82 were listed were because of age. After a median wait
of 107 days, 62 alternates underwent transplantation. Median alternate recipient age
was 67 years (vs 54 years, P  .001). Median donor age was 45 years (vs 31 years,
P .001). Survival for alternates at 90 days was 82% (vs 91%, P .04). Significant
recipient predictors of early mortality on multivariable analysis (n  463) were
previous cardiac surgery (odds ratio 2.74, 95% confidence interval 1.37-5.48) and
renal dysfunction (odds ratio 1.39, 1.10-176). Alternate listing did not independently
predict early or late mortality. Late (90 days) death rates per 1000 person-months
were 4.3 and 3.6 for groups I and II (relative risk 1.2, 0.62-2.36).
Conclusions: Use of two adult recipient lists facilitated allocation of unused
donor organs. Satisfactory long-term survival supports the use of an alternate
recipient list.
As wait times for heart transplant recipients increase, nonstandarddonor hearts are being used for higher risk recipients and forstatus I (critically ill) patients, while older recipients are poten-tially not listed.1-6 In such cases the risk/benefit ratio justifies sucha donor while expanding the pool of available hearts. Despite this,as many as 40% of organs remain unused, prompting our program
to create an alternate recipient list in 1992. Borderline recipients who otherwise
would be excluded from transplantation were considered for the alternate list and,
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once accepted, were educated as to the possible risk factors
associated with the donor hearts that would be assigned to
them.
Patients and Methods
Patients
This report includes all patients entered to December 1999. All
those who have undergone transplantation have at least 1 year of
follow-up. Age was the only absolute criterion for alternate recip-
ient listing. Until 1998, age for placement on the alternate list was
greater than 65 years. In 1998 this age was raised to 70 years.
Since 1999, patients between 65 and 70 years have been offered
the option of regular listing combined with alternate listing. Also
included on the alternate list were patients with moderate renal
insufficiency or peripheral vascular disease. Informed consent was
obtained from all patients at the time of listing. The final consent
to accept an organ was made after a discussion that included both
the treating surgeon and the cardiologist. The use of two adult lists
for heart transplantation was reviewed by our hospital ethics
committee.
Comparison Group
Alternates who underwent transplantation (group I) were com-
pared with 401 consecutive patients (12 years old) who could
have accepted the donor hearts by virtue of size (group II). This
contemporaneous cohort underwent heart transplantation accord-
ing to the criteria delineated in the 24th Bethesda Conference.7
Urgent priority (status I) was not offered to alternate recipients so
that they would not be competing for organs with regularly listed
patients. Outpatient assist device placement was, however, permit-
ted.
Donor Heart Allocation
Donor hearts were considered nonstandard as outlined in Appen-
dix Table 1.8 These were first offered by third-party organ pro-
curement organizations to regularly listed patients according to
United Network for Organ Sharing geographic allocation guide-
lines. Nonstandard hearts were used by us or others for regularly
listed patients, usually waiting as status I. If the heart was refused
by us (for example, if it was hepatitis C seropositive and the
recipient was young or refused such a donor), then we instructed
the organ procurement organization to call us back if the heart
remained unused. We then considered the organ for alternate
recipients.3
Preservation
Preservation solution consisted of University of Wisconsin solu-
tion.9 Reperfusion consisted of leukocyte-depleted, aspartate- and
glutamate-enriched, warm blood cardioplegia (Buckberg solution)
for 3 to 4 minutes, followed by leukocyte-depleted blood (8
minutes). Separate anastomoses of the superior and inferior venae
cavae were used for the right atrium.10
Immunosuppression and Prevention of Infection
Methylprednisolone (7 mg/kg) was given on reperfusion, on sep-
aration from cardiopulmonary bypass, and at a dose of 125 mg
every 12 hours for three doses. Cyclosporine was administered
with the aim of achieving a level of 250 ng/mL. Azathioprine was
administered at 2 mg/kg and at half dose for older recipients
(unusually65 years old) not exhibiting rejection. Prednisone was
initiated at 1 mg/(kg  d) and tapered to 0.1 mg/(kg  d) during
the course of 3 months.11 For those patients with few rejections,
complete weaning from steroids was attempted. Since July 1994,
all patients have received pravastatin after the operation. Older
recipients (65 years old) showing absence of rejection were
targeted for lower cyclosporine levels (by 10%-20%).
In case of cytomegalovirus positivity in either the donor or
recipient, ganciclovir was administered intravenously for 2 weeks
at a dose of 2.5 to 5.0 mg/(kg  d), adjusted for renal function.
This was followed by per os administration for 3 months at a dose
of 1 to 3 g/d. This was extended for an additional 3 months if
rejection (and treatment) or chronic illness occurred. Double-
strength trimethoprim-sulfamethoxazole tablets (160-800 mg)
were administered twice daily 2 days per week for 6 months. An
additional 6-months course was repeated if patients had been
treated for rejection during the 6 months before planned cessation.
Clotrimazole (10 mg) was administered as a lozenge three times
daily for 3 months and extended in the case of treatment for
rejection. Beyond 6 months after the operation, influenza vaccina-
tion was recommended for patients who exhibited a low risk of
rejection.
Statistical Methods
Analysis was performed with Excel 97 (Microsoft Corp, Red-
mond, Wash), SPSS 8.0 (SPSS Inc, Chicago, Ill), and STATA
(Stata Corporation, College Station, Tex). Averages were com-
pared with the Student t test, and proportions were compared with
the Pearson 2. Kaplan-Meier analysis with log rank test was used
for survival and freedom from graft coronary artery disease
(CAD). P values were calculated with the Wilcoxon rank-sum test
for continuous variables and the Fisher exact test for categoric
variables.
Regression models were used to study covariates (Appendix
Table 2A), including the designation of alternate recipient. Early
and late mortality and graft CAD-free survival for all patients (n
463) were analyzed; 95% confidence intervals (CIs) are shown
when available. A separate analysis was used to study early mor-
tality among alternate list patients only (n 62). Selection models
were used on a backward-stepping algorithm with Premove of .15
and Penter of .10. The global test of proportional hazard assump-
tions (for Cox regression analysis of long-term outcome) was
based on Schoenfeld residuals. Plots of natural log of survival for
categories of the selected independent variables versus natural log
of time did not show gross violations regarding proportionality
assumptions.
Results
Listed Patients
One hundred two alternate recipients aged 34 to 74 years
were listed (Table 1). Of those listed, 82 were on the
alternate list for advanced age alone. More than half had
ischemic cardiomyopathy, and 84% were male. Median
maximum oxygen consumption was 12.4 mL/(kg  min).
Sixty-two alternates underwent heart transplantation to De-
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cember 1999. Four patients were removed from the list for
malignancy, and 10 died while waiting. Two patients re-
ceived an electric HeartMate (Thoratec Corporation (Pleas-
anton, Calif).) assist device; both were discharged. One has
died, and 1 continues to wait. Neither was listed status I at
any time.
Donors
From July 1992 to 1999, our institution accepted 182 non-
standard donor hearts. Of these, 120 went to regular list
patients and 62 were allocated to alternates. The median
donor age for transplanted alternates was 45 years, com-
pared with 31 among regularly listed transplant recipients
(P  .001). Median donor/recipient height ratios were com-
parable for both groups (1.01 vs 1.01, P  .64). Donors
allocated to alternate recipients more often had atraumatic
intracranial bleeding (aICB) as a cause of death (50% vs
31%, P  .006). Of the 62 alternates, 25 came from local
area, defined as a travel time of less than 60 minutes by any
mode of transportation. Median graft ischemia time was
significantly longer for alternates (197 minutes vs 181 min-
utes, P  .003). The most common donor risks for alter-
nates were high inotrope requirement, left ventricular hy-
pertrophy (LVH), CAD, or hepatitis C seropositivity (Table
2).
Recipients
Recipients for the alternate and comparison groups are
summarized in Table 3. Alternates were older and more
frequently had undergone previous cardiac surgery. They
also had decreased renal function relative to the others.
Alternate recipients had shorter waiting times than did sta-
tus II regular list patients (107 vs 158 days, P  .04). Four
alternates were 65 years old, and 6 were less than 60 years
old. Thirty-seven were aged 65 to 70 years old, and 15 were
older than 70 years. The oldest recipient was 74 years old.
During the study period, the number of alternate recipient
transplants increased as much as 14 per year, shadowing an
increase in the number of newly listed alternates (Figure 1).
During the same period our program’s volume increased
from 60 to 70 patients/y to 90 to 1000 patients/y. In 1998,
when age for inclusion on the alternate list was raised from
65 to 70, the number of newly listed alternates decreased by
39%, and we observed a parallel decrease in the number of
transplantations among patients on the alternate list. In the
comparison group, 229 of 401 recipients (57%) were status
I. Of these 229 patients, 51% received non-standard donor
hearts. One percent of those in the comparison group who
were status II received a nonstandard heart. This was due to
previous knowledge of borderline stability and virtually
class IV symptoms but not requiring intravenous inotropes.
Twenty-four patients (of 401) in the comparison group were
on a ventricular assist device; 3 patients among the 62
alternates were receiving continuous intravenous inotropic
infusions.
Survival
Three alternates who received hearts with LVH, CAD, and
long distance (heart coming from outside our local area)
died from graft failure. Five others died of recipient risk
TABLE 1. Reasons for listing as alternate recipient (n 
102)
Reason No.
Age alone 82
Retransplantation in combination
Renal insufficiency* 7
Age 2
Peripheral vascular disease 1
Obesity† 1
Other risk factors
Obesity† 4
Peripheral vascular disease 2
Renal dysfunction 1
Jehovah’s Witness 1
Chagas disease 1
*Renal insufficiency according to criterion of serum creatinine level
greater than 2.2 mg/dL.
†Obesity considered to be body mass index greater than 30 kg/m2.
TABLE 2. Risk factors for nonstandard donor hearts initially
refused by our program and other institutions and subse-
quently allocated to alternate recipients (n  62)
Risk factor* No.
High inotropic requirement
Isolated 6
High inotropic requirement plus substance abuse 2
High inotropic requirement plus recent cardiac arrest 2
LVH
Isolated 6
LVH plus high inotropic requirement 2
LVH plus hepatitis C 1
CAD
Isolated 7
CAD plus high inotropic requirement 1
CAD plus LVH 5
CAD plus hepatitis C seropositivity 2
Hepatitis C seropositivity (isolated) 7
Chest trauma with myocardial contusion 5
Smaller donor, no other matches 4
Age  45 y, coronary angiogram not available 4
Extensive intravenous drug abuse with seronegativity for
HIV
3
Reused donor heart† 2
Older age, long ischemia (515 min) 1
Older age, hepatitis C-seropositive spouse 1
Hepatitis B, anti-hepatitis B core antigen (immunoglobulin
G) positive (immunoglobulin M unknown)
1
*Definitions and abbreviations per Appendix Table 1.
†Perioperative massive cerebrovascular accident in recipient.
Laks et al Cardiothoracic Transplantation
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 1 51
TX
factors: 2 from stroke and 3 from multisystem organ failure.
There were 11 in-hospital deaths, translating into a 90-day
survival of 82%. In contrast, the comparison group had
survival of 91% (P  .04) at 90 days. Causes of death are
listed in Appendix Table 3.
Median follow-up time for all 463 patients in this study
was 3.25 years. As of June 2001, a total of 13 alternates had
follow-up beyond 4 years; 12 are still alive. Death rates per
1000 person-mo were 9.0 for alternate recipients and 5.8 for
the comparison group. Overall 4-year survival was 68% (vs
77%, relative risk 1.55, 95% CI 0.96-2.48, P  .11; Figure
2, left). Beyond 90 days, death rate per 1000 person-mo was
4.3 for alternates (vs 3.6, relative risk 1.2; 95% CI 0.62-
2.36, P  .77; Figure 2, right).
Graft Coronary Artery Disease and Rejection
Eleven donor hearts required revascularization (average 1.8
vessels), 10 with bypass grafting and 1 with angioplasty.
Patency of grafts at last follow-up was 63%. As stated
previously, there were 3 early deaths among these patients.
Four other donor hearts also had evidence of CAD but did
not require revascularization. Including these 15 recipients,
4-year freedom from any CAD was 67% (vs 78% for others,
relative risk 1.94; 95% CI 1.10-3.43, P  .04). Excluding
them, freedom from graft CAD was 76% for both groups.
Freedom from grade III rejection at 1 year was 90% (vs
70% for regularly listed transplant recipients, P  .001).11
Eight alternates had one episode each of at least grade III or
presumed rejection.11 Freedom from rejection at 1 year was
90% (vs 70% for regularly listed transplant recipients, P 
.001).
Multivariable Analyses
Survival at Less Than 90 Days (Groups I and II Com-
bined, n  463) Recipient previous cardiac surgery and
poor renal function were risk factors for early mortality.
Odds ratios were 2.74 (95% CI 1.37-5.48) and 1.39 (95% CI
1.10-1.76). Donor death from aICB was also found to be a
risk factor (odds ratio 2.84, 95% CI 1.51-5.34). Goodness-
of-fit 2 in the selection model had a P value of .54. Odds
ratio for alternate listing was 1.36 (95% CI 0.53-3.5; Ap-
pendix Table 2B).
Late Survival Longer Than 90 Days (Groups I and II
Combined, n  463) Donor age and long graft ischemia
time were slight but significant risks. Hazard ratios for these
were 1.30 (95% CI 1.02-1.65) and 1.28 (95% CI 1.05-1.55).
Global test of proportional hazards in this selection model
had a P value of .84. Hazard ratio for alternate listing was
0.85 (95% CI 0.35-2.03). P value for the selection model
was .003 (Appendix Table 2C).
Graft Coronary Artery Disease (Groups I and II Com-
bined, n  463) The only significant predictor of graft
CAD was donor age both by linear (hazard ratio 1.58, 95%
CI 1.23-2.04) and quadratic analyses (hazard ratio 1.43,
95% CI 1.15-1.77). P value for the global test of propor-
tional hazards for this late-occurring event was .10. P value
for the selection model was  .001 (Appendix Table 2D).
TABLE 3. Transplanted recipient characteristics
Characteristic Alternates (n  62) Regular (n  401) P value
Patient demographic variables
Age (y, median and interquartile interval) 67 (3) 54 (17) .001
Gender (% male) 79% 72% .28
Previous cardiac surgery 64% 47% .01
Retransplantation 14% 4% .004
Serum creatinine (mg/dL, median and
interquartile interval)
1.5 (0.8) 1.3 (0.7) .01
Diagnosis
Ischemic cardiomyopathy 60% 45% .04
Dilated cardiomyopathy 21% 33% .08
Graft CAD 14% 3% .001
Congenital heart disease 0 3% .99
Valvular cardiomyopathy 2% 4% .71
Viral cardiomyopathy 2% 3% .99
Postpartum cardiomyopathy 0 2% .6
Other* 2% 8% .11
Median wait (d, interquartile interval)
Status 1 at time of transplant - 29 (112)
Status 2 107 (211) 158 (294) .04
Overall 107 (211) 60 (228) .11
P values were calculated with Wilcoxon rank-sum test for continuous variables and Fisher exact test for categoric variables.
*Other diagnoses included hypertrophic cardiomyopathy (n  3), alcoholic cardiomyopathy (n  2), doxorubicin-induced cardiomyopathy (n  3), acute
rejection (n  1), restrictive cardiomyopathy (n  1), and Marfan syndrome (n  1).
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Early Mortality Among Alternate List Patients (Group
I only, n  62) Only donor cause of death as aICB was
predictive of early mortality for alternate recipients (odds
ratio 9.68; 95% CI 1.59-58.9). Goodness-of-fit 2 P value
for this model was .24. None of the recipient risk factors
tested were found to be significant (Appendix Table 2E).
Discussion
Bridging the gap between organ supply and demand in heart
transplantation may involve limiting the number of listed
recipients to maintain or reduce demand. As the number of
older recipients increases disproportionately, another way is
to limit a shift in the status quo by ensuring that younger
organs are prioritized for younger recipients.2-4 Such strat-
egies are currently applied at the two extremes of life;
organs from donors younger than 19 years old are priori-
tized to those of similar age, whereas many programs set
age limits for enrollment. These broad guidelines do not
address the difference between a 20- and a 70-year-old
recipient.
Increasing supply involves extending the margins of
what is considered acceptable and has led to the widely used
term marginal donor.5,6 Many extracardiac and cardiac fac-
tors may qualify a donor as marginal; this is constantly
being updated. The term nonstandard seems appropriate,
because the only donor criteria on which the transplant
community generally agree are the ideal criteria. These are
age of 45 to 55 years, normal cardiac anatomy and function,
and negative results of serologic studies. Ischemia times
longer than 300 minutes are also generally accepted, but few
opportunities exist to go up to the 500-minute mark.12
Central to the use of nonstandard donors is allocation,
defined as to apportion for a specific purpose or to particular
persons.13 United Network for Organ Sharing guidelines
have acknowledged the fact that not all needs are the same.
Some recipients are listed on a more urgent basis than
others, and this can change. Given the choice between an
assist device and a hepatitis C-seropositive nonstandard
donor, one might allocate such a potentially higher risk
donor heart to a patient in whom the excess risk is justified
(for example, an older patient with previous cardiac sur-
gery). Nonstandard organs would not necessarily be allo-
cated to a much younger recipient who is not in extremis.14
This also depends on the circumstances leading to the
organs being nonstandard. Thus the concept of matching
donor and recipient risk remains fluid and is adjusted for
each individual.
What if there are no available recipients for a nonstand-
ard donor? About a third of such donor organs offered to our
program cannot be allocated, and therefore a strategy to
offer these unused organs to patients who would otherwise
not be offered transplantation (mostly because of age) was
developed. The current single list system for adult recipients
does not formalize this concept. We informed these patients
about the risks involved in using such donor organs and
explained that they are usually turned down or used only for
certain status I patients. We observed that we could decrease
the number of unallocated organs and use them for a spe-
cific group of the potential recipient pool. Median age for
alternate recipients was 67 years, compared with 54 years
for regular list patients. The comparison group comprised
Figure 1. Listed and transplanted alternate recipients.
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all patients that could have potentially used the donor hearts
allocated to the alternates by virtue of size.
We found that between 1992 and 1999 a third of non-
standard organs accepted by our program went to alternates.
This demonstrates that most are being used selectively in
regularly listed recipients in whom the added risk is justi-
fied.8,15,16 Older donors allocated for the alternate list in this
study were always associated with another risk, including
no coronary angiogram available, CAD, or long distance.
Among the 62 alternates, 6 received hearts from donors
older than 45 years old. In this study older donor age
slightly influenced late mortality, as did longer ischemia.
The quadratic effect of donor age on graft CAD may be
explained by a previous observation that early mortality is
increased for the donor age range of 35 to 55 years, reflect-
ing a more cautious selection bias when using older do-
nors.17
Our preservation method was adapted to retrieve higher
risk hearts from outside our local area. Alternate recipients
had longer mean graft ischemia times. We also observed
that the hearts used for alternates came from donors who
more often had died of aICB. This was a risk factor on
multivariable analysis of groups I and II combined and an
even stronger risk when only the alternates were analyzed.
This has been noted to be a sensitive but not specific marker
for both short- and long-term mortalities and is probably a
surrogate for undetected left ventricular hypertrophy.18
Alternates who underwent transplantation were older
than regular list recipients and more frequently had isch-
emic cardiomyopathy. These findings suggest less end-or-
gan reserve and higher risk. The significantly increased
90-day mortality for alternates was explained by the obser-
vation that the risk factors for early mortality in this study
were previous cardiac surgery, poor renal function, and
donor death from aICB. This increased risk (18% vs 9%)
supports keeping these patients on a separate list with con-
sent in advance. Alternates were able to benefit from the
shorter waiting times relative to status II patients on the
regular list (median 107 vs 158 days).
On the basis of our early results, the age for alternate
listing was raised from 65 to 70 years in 1998, according to
the reasoning that heart transplants in those older than 65
years was feasible and should not be withheld. The number
of alternates newly listed and undergoing transplantation
decreased, perhaps reflecting the fact that the current num-
ber of patients older than 70 years who require heart trans-
plantation and are acceptable surgical candidates is low.
Shorter waiting times were also noted. This led to our
current policy of offering both alternate and regular listing
for patients older than 65 years. Alternate listing only is
offered to those older than 70 years.
Three of the early deaths were associated with donor
CAD, LVH, and long distance from the center; we no longer
consider organs with such a triple combination of risk
Figure 2. Actuarial survivals of alternate and regular list heart transplant recipients.
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factors. Individually, donor hearts with these risk factors are
allocated to status I or alternate recipients (CAD) and to
smaller size status I or alternates (LVH). Long distance
aggravates LVH.8 Other deaths were from multisystem or-
gan failure related to recipient risk factors in combination
with generally higher risk donors. Three had renal insuffi-
ciency as well as representing retransplantation. One patient
who died of volvulus illustrates the pathologic features
specific to aging. Multivariable analysis of the factors af-
fecting early mortality specifically in alternates alone did
not show any recipient trends. After 90 days the death rates
for both groups were comparable. On the basis of preoper-
ative maximal oxygen consumption, this current survival is
better than that which would be expected if these patients
did not undergo transplantation.19 A separate report on
quality of life among these generally older recipients is
needed to better define this benefit.
Freedom from rejection for alternates within the first
year was 90%, versus 70% for those on the regular list. This
lower rejection rate was probably due to immunosenescence
in older patients, which permits a reduced immunosuppres-
sion in these patients. All recipients in our institution are
started on cholesterol-lowering therapy.20,21 Alternate recip-
ients did not have increased graft CAD, after those receiving
hearts with preexisting disease were excluded. To date, the
longest survival of a revascularized donor heart is more than
7 years. Donor CAD appeared to be a risk factor for early
graft failure when combined with other factors that aggra-
vated ischemic insult but not independently when selec-
tively used.
Alternate recipients currently account for about 10% of
our program’s yearly transplants. This model may provide a
partial solution for the current increased waiting times for
heart transplantation and the growing number of older re-
cipients. Such a strategy might be complemented by desti-
nation therapy with mechanical devices should these alter-
nately listed patients require continuous inotropic support.
Members of the Heart Transplant Program,
University of California, Los Angeles
Rocky Camara, RN, Fardad Esmailian, MD, Antoine Hage, MD,
Nobuyuki Kawata, MD, Bernard Kubak, MD, Mark Plunkett, MD,
Ali Sadeghi, MD, PhD, Saleh Salehmoghaddam, MD.
References
1. Stevenson LW. When is heart failure a surgical disease? In: Rose EA,
Stevenson LW, editors. Management of end-stage heart disease. New
York: Lippincott-Raven; 1998. p. 129-46.
2. Annual report of the US Scientific Registry of Transplant Recipients
and the Organ Procurement and Transplantation Network: transplant
data 1989-1998 [monograph online] 2000 Feb 21 [cited 2001 Jul 8].
Available from: URL:http://www.unos.org/Data/anrpt_main.htm
3. Renlund DG, Taylor DO, Kfoury AG, Shaddy RS. New UNOS rules:
historical background and implications for transplantation manage-
ment. J Heart Lung Transplant. 1999;18:1065-70.
4. Borkon AM, Muehlebach GF, Jones PG, Bresnahan DR, Genton RE,
Gorton ME, et al. An analysis of the effect of age on survival after
heart transplant. J Heart Lung Transplant. 1999;18:668-74.
5. Sweeney MS, Lammermeier DE, Frazier OH, Burnett CM, Haupt
HM, Duncan JM. Extension of donor criteria in cardiac transplanta-
tion: surgical risk versus supply-side economics. Ann Thorac Surg.
1990;50:7-10.
6. Young JB, Naftel DC, Bourge RC, Kirklin JK, Clemson BS, Porter
CB, et al. Matching the heart donor and heart transplant recipient:
clues for successful expansion of the donor pool: a multivariable,
multiinstitutional report. The Cardiac Transplant Research Database
Group. J Heart Lung Transplant. 1994;13:353-65.
7. Mudge GH, Goldstein S, Addonizio LJ, Caplan A, Mancini D, Levine
TB, et al. 24th Bethesda conference: Cardiac transplantation. Task
Force 3: recipient guidelines/prioritization. J Am Coll Cardiol. 1993;
22:21-31.
8. Laks H, Marelli D, Fazio D, Kobashigawa JA. Expanding the heart
donor base. Curr Opin Organ Transplant. 2000;5:134-8.
9. Stein DG, Drinkwater DC, Laks H, Permut LC, Sangwan S, Chait HI,
et al. Cardiac preservation in patients undergoing transplantation: a
clinical trial comparing University of Wisconsin solution and Stanford
solution. J Thorac Cardiovasc Surg. 1991;102:657-65.
10. Leyh RG, Jahnke AW, Kraatz EG, Sievers HH. Cardiovascular dy-
namics and dimensions after bicaval and standard cardiac transplan-
tation. Ann Thorac Surg. 1995;59:1495-500.
11. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C,
McCallister HA, et al. A working formulation for the standardization
of nomenclature in the diagnosis of heart and lung rejection: Heart
Rejection Study Group. The International Society for Heart Trans-
plantation. J Heart Lung Transplant. 1990;9:587-93.
12. Pflugfelder PW, Thomson D, Singh NR, Menkis AH, McKenzie FN,
Kostuk WJ. Cardiac allograft ischemic time: relation to graft survival
and cardiac function. Circulation. 1989;80(5 Pt 2):III116-21.
13. Webster’s Ninth New Collegiate Dictionary. Springfield (MA): Mer-
riam-Webster; 1990. p. 72.
14. Ong JP, Barnes DS, Younossi ZM, Gramlich T, Yen-Lieberman B,
Goormastic M, et al. Outcome of de novo hepatitis C virus infection
in heart transplant recipients. Hepatology. 1999;30:1293-48.
15. Jeevanandam V, Furukawa S, Prendergast TW, Todd B, Isen HJ,
McClurken JB. Standard criteria for an acceptable donor heart are
restricting heart transplantation. Ann Thorac Surg. 1996;62:1268-75.
16. Young JB. Age before beauty: the use of “older” donor hearts for
cardiac transplantation. J Heart Lung Transplant. 1999;18:488-91.
17. Marelli D, Laks H, Fazio D, Sadeghi A, Ardehali A, Moriguchi J, et
al. The use of marginal donor hearts (abstract). J Heart Lung Trans-
plant. 2000;19:76.
18. Tsai FC, Marelli D, Bresson J, Gjerston D, Kerman R, Patel J, et al.
Use of hearts transplanted from donors with atraumatic intracranial
bleeds. J Heart Lung Transplant. 2002;21:623-8.
19. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson
JR. Value of peak exercise oxygen consumption for optimal timing of
cardiac transplantation in ambulatory patients with heart failure. Cir-
culation. 1991;83:778-86.
20. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK, Boehmer JP,
Brozena SC, et al. Heart transplant coronary artery disease detected by
coronary angiography: a multiinstitutional study of preoperative donor
and recipient risk factors. Cardiac Transplant Research Database.
J Heart Lung Transplant. 1998;17:744-53.
21. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L,
Wang XM, et al. Effect of pravastatin on outcomes after cardiac
transplantation. N Engl J Med. 1995;333:621-7.
Laks et al Cardiothoracic Transplantation
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 1 55
TX
Appendix TABLE 1. Nonstandard donor criteria
Risk factor
Nonstandard
donors* (%) Definition
Cardiac
CAD 5 Any coronary artery stenosis evident on coronary
angiogram or greater than mild calcified plaque
Age 45 y, coronary angiogram not available 2 Normal function on echocardiogram
LVH by electrocardiographic criteria 2 Abnormal R wave on electrocardiogram in V5 and V6
LVH by echocardiogram 15 Posterior wall thickness 14 mm (at least moderate)
Low left ventricular ejection fraction 9 50% on echocardiogram
High-dose inotropic requirement 1 1 inotrope at maximal dose or 2 inotropes at greater
than half maximal dose (dopamine and dobutamine
maximal dose 20 g/[kg  min])
Suspected myocardial contusion secondary to chest trauma 21 Significant anterior blunt chest injury with right
ventricular or septal wall motion abnormality on
echocardiogram
Recent cardiac arrest requiring advanced cardiac life support 15 Organ retrieved less than 24 h after cardiac arrest
Reused donor heart 1 Perioperative cerebrovascular accident in heart
transplantation leading to brain death and organ
donation
Noncardiac
Older age 17 Age 55 y
Hepatitis B seropositivity 1 Immunoglobulin G core antibody positive;
immunoglobulin M unknown
Hepatitis C seropositivity 11 Positive antibody titer
*Figures represent percentages of all nonstandard donors (1992-1999, n  182); 62 of these were allocated to alternates.
Appendix TABLE 2A. Covariates used in the multivariable analysis
Covariate Notes
Recipients
Alternate list patient As defined in this study
Recipient male
Recipient age (standard units  52  15 y) In years
Previous cardiac surgery Any
Retransplantation Retransplantation because of chronic graft CAD
Renal function (standard units  1.5  0.8 mg/dL) Serum creatinine
Donors
Donor male
Donor age (standard units  33  14 y) In years
Donor death from aICB Atraumatic
Graft ischemia time (standard units  193  67) In minutes
Donor history of CAD See Appendix Table 1
Donor LVH Electrocardiographic or echocardiographic criteria (Appendix Table 1)
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Appendix TABLE 2B. Early mortality (n  463)
Logistic regression covariate
Full model (P < .001) Selection model (P < .001)
Odds ratio 95% CI Odds ratio 95% CI
Alternate list patients 1.36 0.53-3.50
Recipient male 0.67 0.30-1.48
Recipient age 0.98 0.67-1.43
Previous cardiac surgery 2.70 1.28-5.68 2.74 1.37-5.48
Retransplantation 1.63 0.53-5.00
Renal function (serum creatinine, standard
units  1.5  0.8 mg/dL)
1.39 1.08-1.79 1.39 1.10-1.76
Donor male 0.85 0.40-1.78
Donor age (standard units  33  14 y) 1.06 0.71-1.59
Donor death from aICB 2.42 1.08-5.40 2.84 1.51-5.34
Graft ischemia time (standard units  193  67 min) 1.20 0.90-1.59
Donor history of CAD 0.88 0.15-5.13
Donor LVH 1.52 0.58-3.95
Goodness-of-fit 2 P value .49 .54
Appendix TABLE 2C. Late mortality (n  463)
Cox regression covariate
Full model (P  .04) Selection model (P  .003)
Hazard ratio 95% CI Hazard ratio 95% CI
Alternate list patients 0.85 0.35-2.03
Recipient male 1.33 0.70-2.53
Recipient age (standard units  52  15 y) 0.82 0.63-1.07
Previous cardiac surgery 1.19 0.70-2.01
Retransplantation 1.74 0.66-4.59
Renal function (serum creatinine, standard units  1.5  0.8 mg/dL) 1.14 0.91-1.43
Donor male 0.80 0.45-1.43
Donor age (standard units  33  14 y) 1.43 1.05-1.95 1.30 1.02-1.66
Donor death from aICB 0.81 0.44-1.50
Graft ischemia time (standard units  193  67 min) 1.32 1.07-1.64 1.28 1.05-1.55
Donor history of CAD 1.11 0.27-4.50
Donor LVH 0.56 0.21-1.52
Global test of proportional hazards P value .56 .84
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Appendix TABLE 2D. Graft CAD-free graft survival (n  463)
Cox regression covariate
Full model (P < .001) Selection model (P < .001)
Hazard ratio 95% CI Hazard ratio 95% CI
Alternate list patients 1.45 0.65-3.26
Recipient male 0.89 0.50-1.59
Recipient age (standard units  52  15 y) 0.86 0.57-1.30
Previous cardiac surgery 0.98 0.58-1.66
Retransplantation 2.15 0.75-6.17
Renal function (serum creatinine, standard units  1.5  0.8 mg/dL) 1.01 0.78-1.32
Donor male 1.56 0.87-2.79
Donor age (standard units  33  14 y)
Linear 1.45 1.08-1.96 1.58 1.23-2.04
Quadratic 1.40 1.82-1.26 1.43 1.15-1.77
Donor death from aICB 1.26 0.71-2.24
Graft ischemia time (standard units  193  67) 0.98 0.76-1.27
Donor history of CAD 1.26 0.40-3.99
Donor LVH 1.10 0.53-2.28
Global test proportional hazards P value .43 .1
Appendix TABLE 2E. Early mortality among alternate list recipients (n  62)
Logistic regression covariate
Full model (P  .09) Selection model (P  .002)
Odds ratio 95% CI Odds ratio 95% CI
Recipient age (standard units  52  15 y) 0.37 0.04-3.58
Previous cardiac surgery 1.54 0.22-11.0
Retransplantation 0.21 0.00-11.0
Renal function (serum creatinine, standard units  1.5  0.8 mg/dL) 1.27 0.40-4.00
Donor male 3.88 0.52-29.0
Donor age (standard units  33  14 y) 0.82 0.28-2.36
Donor death from aICB 8.22 0.93-72.8 9.68 1.59-58.9
Graft ischemia time (standard units  193  67) 1.76 0.85-3.63
Donor history of CAD 1.47 0.16-13.6
Donor LVH 1.46 0.22-9.67
Goodness-of-fit 2 P value .23 .24
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Appendix TABLE 3. Patient deaths
Cause of death
Alternates
(n  62)
Regular
(n  401) P value
All deaths 21 93
90 d after operation .97
Graft failure 3 7
Infection 2 6
Rejection 1 5
Multisystem organ failure 3 12
Cerebrovascular accident 2 4
Other 0 2
Total 11 36
90-d actuarial survival 82% 91%
90 d-1 y after operation .88
Infection 0 2
Rejection 1 6
Graft CAD 0 4
Multisystem organ failure 1* 4
Cerebrovascular accident 0 2
Other 0 1
Not stated 0 2
Total 3 21
1-y actuarial survival 77% 86%
1 y after operation .36
Graft failure 0 1
Infection 0 4
Rejection 0 4
Graft CAD 2 7
Multisystem organ failure 2 3
Cerebrovascular accident 0 1
Cancer 1 1
Pulmonary embolism 1 1
Other 0 7
Not stated 1 7
Total 7 36
P values testing the equality of distributions of deaths between the two groups were calculated by Fisher exact test for categoric variables.
*Sigmoid volvulus.
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